<DOC>
	<DOC>NCT00530621</DOC>
	<brief_summary>The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for patients who have advanced or metastatic non-small cell lung cancer.</brief_summary>
	<brief_title>Study of Enzastaurin Versus Placebo With Pemetrexed for Patients With Advanced or Metastatic Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Laboratory confirmed diagnosis of NSCLC with locally advanced or metastatic disease which cannot be cured. Patients must have disease which progressed after 1 prior systemic cytotoxic chemotherapy regimen for advanced disease. At least 1 measurable lesion. Must have stopped all previous systemic therapies for cancer for at least 2 weeks prior to enrollment. Must be able to follow study guidelines and be able to show up for appointments. Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Previous treatment with enzastaurin or pemetrexed. Concurrent administration of any other antitumor therapy. Inability to swallow tablets Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>